LYTIR

Company · CRDF

Cardiff Oncology, Inc.

Nasdaq's symbol directory lists CRDF on Nasdaq as “Cardiff Oncology, Inc. - Common Stock”.

In the 12 months to Nov 8, 2026: insiders bought on 4 occasions ($1.1M); 3 company reports (Form 8-K, since May 26, 2026).

All insider filings at the SEC

Insider purchases and sales, by month (last 12 months)Insider purchases: $1.1M in total; Insider sales: $0 in total.Jun: Insider purchases $66KJul: Insider purchases $1.0MDecJanFebMarAprMayJunJulAugSepOctNov
Insider purchases above the line: $1.1MInsider sales below: $0
Dollar value of open-market purchases and sales reported on SEC Form 4, by the month traded. Sales include pre-arranged 10b5-1 plan sales.

Insider trades · SEC Form 4

Those inside the hall

Open-market purchases and sales only. Legs one person filed for one day are combined.

Who traded

  1. Gary W. Pace bought on 2 days latest Jul 14, 2026 bought $1.0M
  2. Mani Mohindru, Chief Executive Officer bought on 2 days latest Jul 14, 2026 bought $80K
Every trade (4)
  1. BUYGary W. Pace bought Jul 14, 2026 687,285 shares filing $1.0M
  2. BUYMani Mohindru, Chief Executive Officer bought Jul 14, 2026 34,364 shares filing $50K
  3. BUYGary W. Pace bought Jun 18, 2026 30,000 shares filing $37K
  4. BUYMani Mohindru, Chief Executive Officer bought Jun 18, 2026 24,703 shares filing $30K

Company reports · SEC Form 8-K

In its own words

Current reports the company filed with the SEC; most items are due within four business days of the event. Each line lists the report's items by the SEC's own titles; the filing says what happened. Reports collected since May 26, 2026; every 8-K at the SEC.

  1. Departure or appointment of directors or officers; Amendments to articles or bylaws; change in fiscal year; Regulation FD disclosure filing Oct 27, 2026
  2. Submission of matters to a vote of security holders filing Oct 22, 2026
  3. Entry into a material definitive agreement; Regulation FD disclosure filing Sep 14, 2026

Sources: SEC EDGAR (Forms 4, 144 and 8-K) and STOCK Act periodic transaction reports. Filings can be late, amended or wrong at the source; see methodology.